Subscribe

Risk Factors for Interstitial Lung Disease Following Gefitinib Therapy

Purpose:

To identify a patient with a non-small cell lung cancer (NSCLC) who may be at risk for interstitial fibrosis following gefitinib therapy.

Specialty:

Hematology Oncology
Pulmonology & Critical Care

Objective:

risk factors, adverse effects

ICD-10:

T45.1

Description:

Ando et al listed risk factors for interstitial fibrosis occurring in a patient with non-small cell lung cancer (NSCLC) treated with gefitinib. These can help to identify a patient who should be monitored for this complication. The authors are from Kyoto University, Kinki University, Shizuoka Cancer Center, Osaki City General Hospital, Tokai University and the Aichi Cancer Center in Japan.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone